Syros Pharmaceuticals, Inc. (SYRS)

NASDAQ: SYRS · IEX Real-Time Price · USD

5.10

+0.03 (0.59%)

At close: Apr 25, 2024, 4:00 PM

5.04

-0.06 (-1.18%)

After-hours: Apr 25, 2024, 7:07 PM EDT

Syros Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Revenue	9.94	14.88	23.49	15.09	1.98	2.05	1.1	0.32	0.32	0
Revenue Growth (YoY)	-33.23%	-36.65%	55.62%	661.50%	-3.32%	86.19%	247.32%	0%	-	-
Gross Profit	9.94	14.88	23.49	15.09	1.98	2.05	1.1	0.32	0.32	0
Selling, General & Admin	28.28	29.3	23.04	21.33	21.48	16.16	13.89	10.46	5.73	2.51
Research & Development	108.15	111.94	99.87	76.07	58.25	50.18	41.9	37.82	24.41	10.92
Other Operating Expenses	2.49	9.51	0	0	0	0	0	0	0	0
Operating Expenses	138.92	150.75	122.91	97.39	79.72	66.35	55.79	48.28	30.14	13.44
Operating Income	-128.99	-135.87	-99.42	-82.3	-77.74	-64.3	-54.69	-47.96	-29.82	-13.44
Interest Expense / Income	5.13	4.13	3.91	1.79	0.07	0	0	0	0	0
Other Expense / Income	30.46	-45.35	-16.77	-0.05	-2.38	-2.02	-0.68	-0.22	-0	-0
Pretax Income	-164.57	-94.65	-86.56	-84.04	-75.44	-62.28	-54.01	-47.74	-29.82	-13.43
Net Income	-164.57	-94.65	-86.56	-84.04	-75.44	-62.28	-54.01	-47.74	-29.82	-13.43
Preferred Dividends	0	0	0	0	0	0	0	3.68	4.93	2.21
Net Income Common	-164.57	-94.65	-86.56	-84.04	-75.44	-62.28	-54.01	-51.42	-34.75	-15.64
Shares Outstanding (Basic)	28	13	6	5	4	3	3	1	0	0
Shares Outstanding (Diluted)	28	13	6	5	4	3	3	1	0	0
Shares Change	124.24%	102.00%	35.79%	14.49%	23.17%	28.53%	100.11%	541.14%	29.85%	-
EPS (Basic)	-5.81	-7.49	-13.84	-18.20	-18.80	-19.10	-21.30	-40.50	-175.50	-102.60
EPS (Diluted)	-5.81	-7.49	-13.84	-18.20	-18.80	-19.10	-21.30	-40.50	-175.50	-102.60
Free Cash Flow	-108.42	-124.31	-100.79	-60.7	-72.78	-41.69	-45.55	-42.86	-24.21	-12.17
Free Cash Flow Per Share	-3.83	-9.84	-16.12	-13.18	-18.09	-12.77	-17.93	-33.76	-122.23	-79.80
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	-
Operating Margin	-1298.19%	-913.13%	-423.28%	-545.27%	-3922.35%	-3136.39%	-4966.94%	-15130.28%	-9406.94%	-
Profit Margin	-1656.34%	-636.12%	-368.52%	-556.80%	-3806.16%	-3038.00%	-4905.54%	-16222.08%	-10962.78%	-
Free Cash Flow Margin	-1091.17%	-835.39%	-429.09%	-402.17%	-3672.10%	-2033.66%	-4137.15%	-13519.87%	-7635.96%	-
EBITDA	-157.12	-87.55	-79.63	-79.21	-72.64	-60.67	-52.48	-46.47	-29.22	-13.17
EBITDA Margin	-1581.31%	-588.39%	-339.04%	-524.82%	-3665.19%	-2959.71%	-4766.85%	-14659.31%	-9216.40%	-
Depreciation & Amortization	2.33	2.97	3.02	3.04	2.72	1.6	1.53	1.27	0.6	0.26
EBIT	-159.45	-90.52	-82.65	-82.25	-75.37	-62.28	-54.01	-47.74	-29.82	-13.43
EBIT Margin	-1604.74%	-608.33%	-351.89%	-544.93%	-3802.52%	-3037.95%	-4905.54%	-15060.88%	-9406.31%	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).